ZLAB Zai Lab Ltd

Price (delayed)

$47.08

Market cap

$4.61B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.91

Enterprise value

$3.78B

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
ZLAB's gross profit has surged by 186% year-on-year and by 20% since the previous quarter
Zai Lab's revenue has soared by 181% YoY and by 18% from the previous quarter
The equity has grown by 30% YoY but it has contracted by 5% from the previous quarter
The EPS has grown by 22% from the previous quarter but it has contracted by 10% YoY
The debt has grown by 15% from the previous quarter

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
97.91M
Market cap
$4.61B
Enterprise value
$3.78B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.47
Price to sales (P/S)
26.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.12
Earnings
Revenue
$170.93M
EBIT
-$553.96M
EBITDA
-$540.09M
Free cash flow
-$493.19M
Per share
EPS
-$5.91
Free cash flow per share
-$5.16
Book value per share
$13.57
Revenue per share
$1.79
TBVPS
$15.61
Balance sheet
Total assets
$1.5B
Total liabilities
$192.91M
Debt
$17.89M
Equity
$1.31B
Working capital
$1.24B
Liquidity
Debt to equity
0.01
Current ratio
8.99
Quick ratio
8.76
Net debt/EBITDA
1.54
Margins
EBITDA margin
-316%
Gross margin
64.7%
Net margin
-324.1%
Operating margin
-324.5%
Efficiency
Return on assets
-32.9%
Return on equity
-37.3%
Return on invested capital
-195.3%
Return on capital employed
-41.2%
Return on sales
-324.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
4%
1 week
21.09%
1 month
22.29%
1 year
-68.39%
YTD
-25.09%
QTD
35.76%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$170.93M
Gross profit
$110.56M
Operating income
-$554.65M
Net income
-$553.96M
Gross margin
64.7%
Net margin
-324.1%
ZLAB's gross profit has surged by 186% year-on-year and by 20% since the previous quarter
Zai Lab's revenue has soared by 181% YoY and by 18% from the previous quarter
The company's operating margin has surged by 57% YoY and by 34% QoQ
The net margin has soared by 57% YoY and by 34% from the previous quarter

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
3.47
P/S
26.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.12
The EPS has grown by 22% from the previous quarter but it has contracted by 10% YoY
The stock's P/B is 42% below its last 4 quarters average of 6.0
The equity has grown by 30% YoY but it has contracted by 5% from the previous quarter
Zai Lab's revenue has soared by 181% YoY and by 18% from the previous quarter
ZLAB's price to sales (P/S) is 69% lower than its last 4 quarters average of 85.4

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has surged by 85% YoY and by 54% QoQ
The ROS has soared by 57% YoY and by 34% from the previous quarter
The ROA has grown by 26% from the previous quarter and by 18% YoY
ZLAB's ROE is up by 25% QoQ and by 17% YoY

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The company's total liabilities has surged by 59% YoY but it fell by 16% QoQ
The total assets has grown by 33% YoY but it has contracted by 7% from the previous quarter
The debt is 99% less than the equity
Zai Lab's debt to equity has plunged by 50% YoY
The equity has grown by 30% YoY but it has contracted by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.